2011Chinese Journal of Practical OphthalmologyRequires access

Intravitreal bevacizumab and Ahmed glaucoma valve implantation in patients with neovascular glaucoma

Haitao Zhang, Baojun Wang, Jun-Xi Hu, Yingying Xu, Lam Wai-Ching

Open publisher page 0 citations

Abstract

Objective To explore the efficacy and complication of intravitreal bevacizumab and Ahmed glaucoma valve implantation in patients with neovascular glaucoma (NVG). Methods NVG patients received the treatment of intravitreal bevacizumab 0.05mL/1.25mg and Ahmed glaucoma valve implantation were retrospectively selected. Subjects received ocular examinations before operation and routine follow-ups after operation, and information including the number of anti-glaucoma medications,Snellen visual acuity and IOP measured by Goldmann applanation tonometer was recorded. Success was defined as an IOP between 6-2lmmHg, without any or with no more additional anti-glaucoma medications, no need of additional glaucoma surgery, and none loss of light perception. Results Thirty-five cases (35eyes) were included and follow up time was 24.6:± 14.2m. Afier Ahmed valve implantation, IOP was decreased compared with pre-IOP (P <0.01), of which were 44.9± 4.8mmHg (pre-op),.18.2± 4.0mmHg (6 m), 15.5± 3.3mmHg (1 y) and 9.8± 2.6mmHg (3 y). The number of anti-glaucoma medications was decreased compared with pre-number (P <0.01), of which were 3.3± 0.5(pre-op), 0.9± 0.5 (6 m), 0.8± 0.9 (1 y) and 0.8± 0.6 (3 y). At last follow up, there were 19 cases (54.3%) with stable visual acuity, 4 cases (11.4%) with visual improvement, 12 cases (34.3%) with worse visual acuity, 3 (8.6%) loss light perception. There were 7 cases (20.0%) failed during 3-year follow up period. The cumulative survival rates were 82.9% (1 y), 74.1% (2 y) and 71.0%(3 y) respectively by Kaplan-Meier sruvival analysis. Cox stepwise regression analysis found that the survival time was significant associated with the preop-visual acuity <2/400 (RR=3.571, P <0.05). Post-op complications occurred in 8 eyes (22.9%), of which hyphema in 2 eyes (5.7%), choroidal effusion in 2 eyes (5.7%). Other complications occurred infrequently and implants were not removed in any of the patients. Conclusions Being safe and effective, the procedure of intravitreal bevacizumab and Ahmed glaucoma valve implantation should be one of treatments to NVG. Key words: Ahmed glaucoma valve;  Neovascular glaucoma;  Bevacizumab;  Intravitreal injection

About this research paper

What this paper is about

Objective To explore the efficacy and complication of intravitreal bevacizumab and Ahmed glaucoma valve implantation in patients with neovascular glaucoma (NVG). Methods NVG patients received the treatment of intravitreal bevacizumab 0.05mL/1.25mg and Ahmed glaucoma valve implantation were retrospectively selected. Subjects received ocular examinations before operation and routine follow-ups after operation, and information including the number of anti-glaucoma medications,Snellen visual acuity and IOP measured by Goldmann applanation tonometer was recorded. Success was defined as an IOP between 6-2lmmHg, without any or with no more additional anti-glaucoma medications, no need of additional glaucoma surgery, and none loss of light perception. Results Thirty-five cases (35eyes) were included and follow up time was 24.6:± 14.2m. Afier Ahmed valve implantation, IOP was decreased compared with pre-IOP (P <0.01), of which were 44.9± 4.8mmHg (pre-op),.18.2± 4.0mmHg (6 m), 15.5± 3.3mmHg (1 y) and 9.8± 2.6mmHg (3 y). The number of anti-glaucoma medications was decreased compared with pre-number (P <0.01), of which were 3.3± 0.5(pre-op), 0.9± 0.5 (6 m), 0.8± 0.9 (1 y) and 0.8± 0.6 (3 y). At last follow up, there were 19 cases (54.3%) with stable visual acuity, 4 cases (11.4%) with visual improvement, 12 cases (34.3%) with worse visual acuity, 3 (8.6%) loss light perception. There were 7 cases (20.0%) failed during 3-year follow up period. The cumulative survival rates were 82.9% (1 y), 74.1% (2 y) and 71.0%(3 y) respectively by Kaplan-Meier sruvival analysis. Cox stepwise regression analysis found that the survival time was significant associated with the preop-visual acuity <2/400 (RR=3.571, P <0.05). Post-op complications occurred in 8 eyes (22.9%), of which hyphema in 2 eyes (5.7%), choroidal effusion in 2 eyes (5.7%). Other complications occurred infrequently and implants were not removed in any of the patients. Conclusions Being safe and effective, the procedure of intravitreal bevacizumab and Ahmed glaucoma valve implantation should be one of treatments to NVG. Key words: Ahmed glaucoma valve;  Neovascular glaucoma;  Bevacizumab;  Intravitreal injection

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To explore the efficacy and complication of intravitreal bevacizumab and Ahmed glaucoma valve implantation in patients with neovascular glaucoma (NVG). Methods NVG patients received the treatment of intravitreal bevacizumab 0.05mL/1.25mg and Ahmed glaucoma valve implantation were retrospectively selected. Subjects received ocular examinations before operation and routine follow-ups after operation, and information including the number of anti-glaucoma medications,Snellen visual acuity and IOP measured by Goldmann applanation tonometer was recorded. Success was defined as an IOP between 6-2lmmHg, without any or with no more additional anti-glaucoma medications, no need of additional glaucoma surgery, and none loss of light perception. Results Thirty-five cases (35eyes) were included and follow up time was 24.6:± 14.2m. Afier Ahmed valve implantation, IOP was decreased compared with pre-IOP (P <0.01), of which were 44.9± 4.8mmHg (pre-op),.18.2± 4.0mmHg (6 m), 15.5± 3.3mmHg (1 y) and 9.8± 2.6mmHg (3 y). The number of anti-glaucoma medications was decreased compared with pre-number (P <0.01), of which were 3.3± 0.5(pre-op), 0.9± 0.5 (6 m), 0.8± 0.9 (1 y) and 0.8± 0.6 (3 y). At last follow up, there were 19 cases (54.3%) with stable visual acuity, 4 cases (11.4%) with visual improvement, 12 cases (34.3%) with worse visual acuity, 3 (8.6%) loss light perception. There were 7 cases (20.0%) failed during 3-year follow up period. The cumulative survival rates were 82.9% (1 y), 74.1% (2 y) and 71.0%(3 y) respectively by Kaplan-Meier sruvival analysis. Cox stepwise regression analysis found that the survival time was significant associated with the preop-visual acuity <2/400 (RR=3.571, P <0.05). Post-op complications occurred in 8 eyes (22.9%), of which hyphema in 2 eyes (5.7%), choroidal effusion in 2 eyes (5.7%). Other complications occurred infrequently and implants were not removed in any of the patients. Conclusions Being safe and effective, the procedure of intravitreal bevacizumab and Ahmed glaucoma valve implantation should be one of treatments to NVG. Key words: Ahmed glaucoma valve;  Neovascular glaucoma;  Bevacizumab;  Intravitreal injection

Key concepts: Medicine, Glaucoma valve, Glaucoma, Ophthalmology, Visual acuity, Neovascular glaucoma, Bevacizumab, Intraocular pressure

Related papers

Back to paper searchBrowse research topicsOriginal source
Intravitreal bevacizumab and Ahmed glaucoma valve implantation in patients with neovascular glaucoma — Research Paper | ScholarLens